Skip to main content
TipRanks
Go Ultimate75% OFF

IRLAB Therapeutics AB Class A (IRLAB.A) AI Stock Analysis

1 Followers
SE:IRLAB.A

IRLAB Therapeutics AB Class A

(Nasdaq OMX AB:IRLAB.A)

Select Model
Rating:37Underperform
Price Target:SEK 0.79â–¼(-6.49% Downside)
Action:reiterated
Date:11/16/26

The stock scores at the absolute bottom of the range, reflecting a convergence of severe risks. The primary driver is a state of financial distress marked by collapsing revenues and massive cash burn that threatens the company's survival. This is reinforced by a bearish technical trend with the stock in a clear downtrend and deeply oversold, alongside a negative P/E ratio that underscores its lack of profitability. The company's low debt is the only minor positive, but it is completely overshadowed by the unsustainable operating model.

Positive Factors
Improved Balance Sheet LeverageThe sharp reduction in debt-to-equity indicates materially lower financial strain than in prior years and gives IRLAB a stronger solvency position. This improvement can preserve flexibility for continued research spending and reduce the balance-sheet burden while clinical programs advance.
Negative Factors
Persistent UnprofitabilityThe company has not re-established a stable earnings base after losing profitability, and negative gross profit means current revenue does not cover direct costs. Continued losses can erode equity, constrain investment choices, and keep profitability dependent on successful development outcomes.

IRLAB Therapeutics AB Class A (IRLAB.A) vs. iShares MSCI Sweden ETF (EWD)

-80%-60%-40%-20%0%20%40%SE:IRLAB.A-61.65%EWD+17.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 126.11M
Dividend Yield
―
Average Volume (3M)
2.52M
Price to Earnings (P/E)
-1.7
Beta (1Y)
0.42
Revenue Growth
-21.20%
EPS Growth
68.24%
Country
Sweden
Employees
31
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

IRLAB Therapeutics AB Class A Business Overview & Revenue Model

Company Description

IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, and Pirepemat,...

How the Company Makes Money

IRLAB Therapeutics primarily generates revenue through collaboration and partnering arrangements for its drug candidates, which can include upfront payments, research funding, development and regulatory milestone payments, and royalties on future net...

IRLAB Therapeutics AB Class A Financial Statement Overview

Summary

Financial health is extremely poor. The company suffers from collapsing revenues, deeply negative margins, and massive, persistent cash burn that is rapidly eroding its equity base. The only mitigating factor is a recently improved, low-debt balance sheet, but this is insufficient to offset the severe operational distress.

Income Statement

8Very Negative

Balance Sheet

35Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue67.42M57.46M94.63M5.68M61.14M207.78M
Gross Profit-43.72M-92.35M-92.42M-122.73M-111.23M168.69M
EBITDA-39.60M-88.03M-68.07M-173.32M-109.13M56.05M
Net Income-46.76M-110.01M-83.13M-177.84M-114.20M51.78M
Balance Sheet
Total Assets153.86M138.21M136.21M177.12M323.56M472.45M
Cash, Cash Equivalents and Short-Term Investments90.64M81.86M66.92M111.31M252.78M401.90M
Total Debt17.93M29.95M60.42M27.57M3.98M6.60M
Total Liabilities73.70M107.49M103.58M61.36M32.72M72.97M
Stockholders Equity80.16M30.72M32.63M115.76M290.83M399.48M
Cash Flow
Free Cash Flow-77.27M-55.22M-65.79M-165.14M-145.99M127.93M
Operating Cash Flow-77.27M-55.22M-65.59M-164.85M-142.61M128.64M
Investing Cash Flow00-199.00K-293.00K-3.38M-708.00K
Financing Cash Flow58.00M73.41M21.40M23.68M-3.13M-3.04M

IRLAB Therapeutics AB Class A Technical Analysis

Technical Analysis SentimentNegative
Last Price0.85

Price Trends

50DMA1.86Negative
100DMA1.67Negative
200DMA1.55Negative

Market Momentum

MACD-0.13Positive
RSI26.87Positive
STOCH24.67Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IRLAB.A, the sentiment is Negative. The current price of 0.85 is below the 20-day moving average (MA) of 1.92, below the 50-day MA of 1.86, and below the 200-day MA of 1.55, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 26.87 is Positive, neither overbought nor oversold. The STOCH value of 24.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:IRLAB.A.

IRLAB Therapeutics AB Class A Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:IRLAB.A against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:SANIONSE:SANION77OutperformSEK 1.64B8.8929.71%―24.98%-31.44%
SE:BIOA.BSE:BIOA.B65NeutralSEK 27.51B260.505.18%0.69%-46.09%-90.13%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ALZCURSE:ALZCUR51NeutralSEK 882.54M10.67105.09%―――
SE:SYNACTSE:SYNACT43NeutralSEK 743.15M-7.07-60.58%――14.35%
SE:IRLAB.ASE:IRLAB.A37UnderperformSEK 126.11M-1.69-75.46%―-21.20%68.24%
SE:ALZSE:ALZ36UnderperformSEK 100.82M-1.88-15.44%―-100.00%40.79%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%SE:IRLAB.ASE:ALZSE:ALZCURSE:BIOA.BSE:SYNACTSE:SANIONDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:IRLAB.A and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:IRLAB.AIRLAB Therapeutics AB Class A0.85-1.39-62.14%
SE:ALZAlzinova AB0.32-1.08-77.20%
SE:ALZCURAlzeCure Pharma AB6.404.60254.77%
SE:BIOA.BBioArctic AB Class B310.0031.4511.29%
SE:SYNACTSynAct Pharma AB13.22-7.18-35.20%
SE:SANIONSaniona AB11.91-4.37-26.84%

IRLAB Therapeutics AB Class A Corporate Events

IRLAB Reports Nine-Month Results and Appoints New Chairman

Nov 13, 2026

IRLAB Therapeutics develops Parkinson’s disease drug candidates through its AI-based research platform, ISP, and a broad development portfolio. The company reported net sales of SEK 52,696 thousand for January–September 2026, compared with SEK 42,739...

IRLAB Shifts Focus to Commercializing Existing Drug Portfolio

Nov 12, 2026

IRLAB said it is redirecting resources toward revenue-generating partnerships, licensing agreements and divestments involving its existing drug portfolio, while reducing investment in new candidate discovery. The company said the likelihood of signin...

IRLAB Announces Q3 2026 Report Presentation and Webcast

Nov 6, 2026

The company will publish its January–September 2026 interim report on November 13 at 07:00 CEST, followed by a Swedish-language webcast featuring its chief executive, research head, and finance chief. The session will provide management commentary an...

IRLAB Wins Key U.S. Patent Boost for Next-Generation Parkinson’s Drug IRL1117

Oct 27, 2026

IRLAB Therapeutics AB, a Gothenburg-based biopharmaceutical company listed on Nasdaq Stockholm, specializes in developing new treatments for Parkinson’s disease across all stages of the illness. Built on research from Nobel Laureate Prof. Arvid Carls...

IRLAB names nomination committee ahead of 2027 AGM

Oct 20, 2026

IRLAB Therapeutics has appointed a nomination committee for its 2027 annual general meeting, in line with a mandate approved by shareholders in 2024. The committee includes representatives of the three largest shareholder groups as of late August 202...

IRLAB Research on Potential First-in-Class Apathy Drug Linepemat Published

Oct 20, 2026

IRLAB Therapeutics said the preclinical research underpinning its investigational drug linepemat, also known as IRL757, has been published in the peer-reviewed journal Bioorganic & Medicinal Chemistry Letters. The molecule was designed to enhance act...

IRLAB to Spotlight Parkinson’s Pipeline at Redeye Neurology Event

Oct 9, 2026

IRLAB Therapeutics AB, a Stockholm-listed biopharma group specializing in novel Parkinson’s disease therapies, is advancing multiple candidates including Mesdopetam, which has completed Phase IIb for levodopa-induced dyskinesias and is being prepared...

IRLAB Therapeutics Names Janne Backman as Chairman to Steer Parkinson’s Pipeline and Partnerships

Sep 24, 2026

IRLAB Therapeutics AB, a Nasdaq Stockholm-listed biopharmaceutical group based in Gothenburg, develops novel Parkinson’s disease therapies from early research through late-stage clinical trials, leveraging a proprietary systems biology platform to ge...

IRLAB CEO to Step Down in 2027 as Parkinson’s Pipeline Advances

Sep 3, 2026

IRLAB Therapeutics’ chief executive Kristina Torfgård has informed the board she intends to step down during the first quarter of 2027, though she will remain in place to ensure a smooth handover while the board launches an immediate search for her s...

IRLAB Therapeutics Updates Share Capital After Completed Rights Issue

Aug 31, 2026

IRLAB Therapeutics AB has updated its share capital structure following the completion of a rights issue and an overallotment issue of ordinary shares of series A, resolved by the board in May and approved by an extraordinary general meeting in June...

IRLAB strengthens Parkinson’s pipeline and finances in Q2 2026

Aug 26, 2026

IRLAB reported second-quarter 2026 net sales of SEK 6.4 million, down from SEK 19.5 million a year earlier, and an operating loss of SEK 16.7 million, while earnings per share improved to a loss of SEK 0.23 versus SEK 0.62. The company’s rights issue...

IRLAB to Webcast Q2 2026 Interim Report as Parkinson’s Pipeline Advances

Aug 20, 2026

IRLAB Therapeutics AB, a Gothenburg-based biotech specializing in novel Parkinson’s disease therapies, is advancing a diversified clinical and preclinical pipeline built on its proprietary systems biology-based research platform. With multiple drug c...

WHO Grants INN Name to IRLAB’s Apathy Drug Candidate Linepemat

Aug 19, 2026

IRLAB Therapeutics AB, a Gothenburg-based biopharmaceutical company specializing in Parkinson’s disease and other neurodegenerative disorders, is building a diversified pipeline of small-molecule drug candidates addressing motor complications, falls...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 16, 2026